These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 30286384)

  • 1. Assessment of change in restless legs syndrome symptoms during the acute drug-withdrawal period.
    Wang A; Foster K; Skeba P; Hiranniramol K; Earley CJ; Allen RP
    Sleep Med; 2018 Dec; 52():80-87. PubMed ID: 30286384
    [No Abstract]   [Full Text] [Related]  

  • 2. Polysomnographic record and successful management of augmentation in restless legs syndrome/Willis-Ekbom disease.
    Maestri M; Fulda S; Ferini-Strambi L; Zucconi M; Marelli S; Staedler C; Bassetti CL; Manconi M
    Sleep Med; 2014 May; 15(5):570-5. PubMed ID: 24767724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopamine agonist withdrawal syndrome in a patient with restless legs syndrome.
    Dorfman BJ; Nirenberg MJ
    Parkinsonism Relat Disord; 2013 Feb; 19(2):269-70. PubMed ID: 22749683
    [No Abstract]   [Full Text] [Related]  

  • 4. Dopamine agonist withdrawal syndrome in a patient with restless legs syndrome without impulse control disorder or drug abuse.
    Shimo Y; Nakajima A; Hattori N
    Neurol Sci; 2015 Jun; 36(6):1021-3. PubMed ID: 25362251
    [No Abstract]   [Full Text] [Related]  

  • 5. Preferential D2 or preferential D3 dopamine agonists in restless legs syndrome.
    Manconi M; Ferri R; Zucconi M; Clemens S; Giarolli L; Bottasini V; Ferini-Strambi L
    Neurology; 2011 Jul; 77(2):110-7. PubMed ID: 21715702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First night efficacy of pramipexole in restless legs syndrome and periodic leg movements.
    Manconi M; Ferri R; Zucconi M; Oldani A; Fantini ML; Castronovo V; Ferini-Strambi L
    Sleep Med; 2007 Aug; 8(5):491-7. PubMed ID: 17512780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Major depression after withdrawing dopamine agonists in two patients with restless legs syndrome and impulse control disorders.
    Launois C; Leu-Semenescu S; Brion A; Arnulf I
    Sleep Med; 2013 Jul; 14(7):696. PubMed ID: 23714418
    [No Abstract]   [Full Text] [Related]  

  • 8. Opioid-induced hyperalgesia and dopamine-induced augmentation in an intractable and refractory case of RLS.
    Chokroverty S
    Sleep Med; 2015 Oct; 16(10):1304. PubMed ID: 26386895
    [No Abstract]   [Full Text] [Related]  

  • 9. A dose-ranging study of pramipexole for the symptomatic treatment of restless legs syndrome: polysomnographic evaluation of periodic leg movements and sleep disturbance.
    Jama L; Hirvonen K; Partinen M; Alakuijala A; Hublin C; Tamminen I; Koester J; Reess J
    Sleep Med; 2009 Jun; 10(6):630-6. PubMed ID: 19171500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sleep laboratory studies in restless legs syndrome patients as compared with normals and acute effects of ropinirole. 1. Findings on objective and subjective sleep and awakening quality.
    Saletu B; Gruber G; Saletu M; Brandstätter N; Hauer C; Prause W; Ritter K; Saletu-Zyhlarz G
    Neuropsychobiology; 2000; 41(4):181-9. PubMed ID: 10828727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adherence and persistence to ropinirole, pramipexole, and gabapentin in patients with newly diagnosed restless legs syndrome.
    Kim J; Hartzema AG
    Sleep Med; 2018 Apr; 44():45-52. PubMed ID: 29530369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sleep laboratory studies in restless legs syndrome patients as compared with normals and acute effects of ropinirole. 2. Findings on periodic leg movements, arousals and respiratory variables.
    Saletu M; Anderer P; Saletu B; Hauer C; Mandl M; Oberndorfer S; Zoghlami A; Saletu-Zyhlarz G
    Neuropsychobiology; 2000; 41(4):190-9. PubMed ID: 10828728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Development of a opioid dependence in a not diagnosed restless legs syndrome].
    Hain C
    Psychiatr Prax; 2002 Sep; 29(6):322-3. PubMed ID: 12402965
    [No Abstract]   [Full Text] [Related]  

  • 14. Gabapentin versus ropinirole in the treatment of idiopathic restless legs syndrome.
    Happe S; Sauter C; Klösch G; Saletu B; Zeitlhofer J
    Neuropsychobiology; 2003; 48(2):82-6. PubMed ID: 14504416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Motor hyperactivity of the iron-deficient rat - an animal model of restless legs syndrome.
    Lai YY; Cheng YH; Hsieh KC; Nguyen D; Chew KT; Ramanathan L; Siegel JM
    Mov Disord; 2017 Dec; 32(12):1687-1693. PubMed ID: 28843017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ropinirole in restless leg syndrome.
    Ahmed I
    Mo Med; 2002; 99(9):500-1. PubMed ID: 12462942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute placebo-controlled sleep laboratory studies and clinical follow-up with pramipexole in restless legs syndrome.
    Saletu M; Anderer P; Saletu-Zyhlarz G; Hauer C; Saletu B
    Eur Arch Psychiatry Clin Neurosci; 2002 Aug; 252(4):185-94. PubMed ID: 12242580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Schizophrenia With Decompensation on Clozapine With Pramipexole.
    Amador EC; Olabisi JL; Cunningham EA
    Prim Care Companion CNS Disord; 2019 Dec; 21(6):. PubMed ID: 31877244
    [No Abstract]   [Full Text] [Related]  

  • 19. Successful discontinuation of oxycodone under pramipexole treatment for restless legs syndrome due to withdrawal.
    Sakurai A; Wakuda T; Yoshida R; Katoh SY; Yamasue H
    Psychiatry Clin Neurosci; 2021 Mar; 75(3):112-113. PubMed ID: 33289253
    [No Abstract]   [Full Text] [Related]  

  • 20. Therapeutic Utility of Opioids for Restless Legs Syndrome.
    Mackie SE; Winkelman JW
    Drugs; 2017 Aug; 77(12):1337-1344. PubMed ID: 28616844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.